The Impact of JAK2V617F Mutation on Different Types of Thrombosis Risk in Patients with Essential Thrombocythemia: a Meta-analysis

Overview

Journal Int J Hematol

Specialty Hematology

Date 2015 May 23

PMID 25997869

Citations 7

Authors

Youwen Qin

Xiaorui Wang

Chuxian Zhao

Chun Wang

Yining Yang

Affiliations

Soon will be listed here.

Abstract

To assess the effect of JAK2V617F on different thrombotic risks in essential thrombocythemia (ET) patients, we identified eligible studies from several databases including Pubmed, Embase, and Cochrane Central Register of Controlled Trials (up to November 2014). Twenty-two studies of 2922 ET patients were included in exploring the relationship between JAK2V617F and the risk of thrombosis. Compared to JAK2V617F-negative ET patients, JAK2V617F-positive ET patients had higher odd risks (ORs) of arterial thrombosis [OR = 2.59 (1.84-3.65)] and venous thrombosis [OR = 2.10 (1.53-2.88)]. The JAK2V617F-positive group was also more prone to increased risk of microcirculatory disturbances [OR = 1.50 (0.97-2.32)]. Moreover, JAK2V617F may indicate increased risk of either arterial [OR = 1.71 (1.22-2.39)] or venous thrombosis [OR = 2.90 (1.54-5.46)] before diagnosis of ET. During follow-up, JAK2V617F might not be related to arterial thrombosis [OR = 1.90 (0.90-2.08)], but rather venous thrombosis [OR = 1.95 (1.08-3.53)]. In conclusion, JAK2V617F increased the risk of arterial and venous thrombosis in ET patients, while understanding its role in microcirculatory disturbances will require further studies.

Citing Articles

JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles.

Hekimoglu H, Toprak S, Sozer S Turk J Haematol. 2022; 39(1):13-21.

PMID: 34981912 PMC: 8886274. DOI: 10.4274/tjh.galenos.2021.2021.0607.

The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms.

Sahin E, Yonal-Hindilerden I, Hindilerden F, Aday A, Nalcaci M Turk J Med Sci. 2021; 52(1):150-165.

PMID: 34482679 PMC: 10734827. DOI: 10.3906/sag-2103-247.

Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta-analysis.

Yang E, Wang M, Wang Z, Li Y, Wang X, Ming J Ann Hematol. 2021; 100(11):2699-2706.

PMID: 34383101 PMC: 8510937. DOI: 10.1007/s00277-021-04617-6.

Recurrent thrombosis of splanchnic and lower extremity arteries with essential thrombocythemia.

Jung S, Jun H SAGE Open Med Case Rep. 2019; 7:2050313X19880079.

PMID: 31632677 PMC: 6767714. DOI: 10.1177/2050313X19880079.

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.

Mejia-Ochoa M, Acevedo Toro P, Cardona-Arias J BMC Cancer. 2019; 19(1):590.

PMID: 31208359 PMC: 6580484. DOI: 10.1186/s12885-019-5764-4.

References

Vardiman J, Lee Harris N, Brunning R . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100(7):2292-302. DOI: 10.1182/blood-2002-04-1199. View

Gangat N, Wassie E, Lasho T, Finke C, Ketterling R, Hanson C . Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. Eur J Haematol. 2014; 94(1):31-6. DOI: 10.1111/ejh.12389. View

Falanga A, Marchetti M . Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2012; 2012:571-81. DOI: 10.1182/asheducation-2012.1.571. View

Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F . Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011; 117(22):5857-9. DOI: 10.1182/blood-2011-02-339002. View

Dahabreh I, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M . Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res. 2008; 33(1):67-73. DOI: 10.1016/j.leukres.2008.06.006. View

Arellano-Rodrigo E, Alvarez-Larran A, Reverter J, Colomer D, Villamor N, Bellosillo B . Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol. 2008; 84(2):102-8. DOI: 10.1002/ajh.21338. View

Moreno M, Lozano M, Roldan V, Bellosillo B, Garcia-Barbera N, Rivera J . JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia. Ann Hematol. 2008; 87(9):763-5. DOI: 10.1007/s00277-008-0474-z. View

Campbell P, Scott L, Buck G, Wheatley K, East C, Marsden J . Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005; 366(9501):1945-53. DOI: 10.1016/S0140-6736(05)67785-9. View

Larsen T, Pallisgaard N, Moller M, Hasselbalch H . High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. Hematology. 2008; 13(2):71-6. DOI: 10.1179/102453308X315960. View

10.

Tefferi A, Vardiman J . Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2007; 22(1):14-22. DOI: 10.1038/sj.leu.2404955. View

11.

Cheng Y, Liu Z, Yao F, Zeng W, Zheng D, Dong Y . Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med. 2013; 10(9):e1001515. PMC: 3775725. DOI: 10.1371/journal.pmed.1001515. View

12.

Murphy S, Peterson P, Iland H, Laszlo J . Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997; 34(1):29-39. View

13.

Cetin G, Ozkan T, Turgut S, Cikrikcioglu M, Ar M, Ayer M . Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis. Mol Biol Rep. 2014; 41(10):6737-42. DOI: 10.1007/s11033-014-3559-x. View

14.

Hsiao H, Yang M, Liu Y, Lee C, Yang W, Liu T . The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Exp Hematol. 2007; 35(11):1704-7. DOI: 10.1016/j.exphem.2007.08.011. View

15.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

16.

Palandri F, Ottaviani E, Salmi F, Catani L, Polverelli N, Fiacchini M . JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. Leuk Lymphoma. 2009; 50(2):247-53. DOI: 10.1080/10428190802688152. View

17.

Stevenson W, Hoyt R, Bell A, Guipponi M, Juneja S, Grigg A . Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. Pathology. 2006; 38(4):336-42. DOI: 10.1080/00313020600820906. View

18.

Tefferi A, Wassie E, Lasho T, Finke C, Belachew A, Ketterling R . Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. 2014; 28(12):2300-3. DOI: 10.1038/leu.2014.148. View

19.

De Stefano V, Rossi E, Za T, Ciminello A, Betti S, Luzzi C . JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis. Am J Hematol. 2011; 86(6):526-8. DOI: 10.1002/ajh.22024. View

20.

Lee H, Park L, Lee E, Lee S, Shin S, Im H . Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea. Clin Lymphoma Myeloma Leuk. 2011; 12(1):70-5. DOI: 10.1016/j.clml.2011.10.002. View